Summary of Study ST003975

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002490. The data can be accessed directly via it's Project DOI: 10.21228/M8SC2K This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples | Perform analysis on untargeted data
Download mwTab file (text) | Download mwTab file(JSON) | Download data files (Contains raw data)

Study ID	ST003975
Study Title	Metabolomic profiles of albendazole treated T. spiralis larval worms
Study Summary	Trichinella spiralis is the parasitic nematodes that cause trichinellosis. Patients are infected with T. spiralis by consuming raw meat containing larval stage of the parasite. Patients may develop weakness, muscle pain, facial edema, or death in severe cases. Albendazole (ABZ) is the drug of choice for trichinellosis, however, the resistance to ABZ has been repeatedly reported. Hence, novel drugs against this parasite are essentially required. Developing new drugs is expensive and time-consuming. To overcome these limitations, the application of computational approaches and drug repurposing strategy would be a suitable solution. Here, we aimed to discover new anthelmintic drugs for T. spiralis using in silico-based techniques and in vitro validation. Firstly, we treated both adult and larval stages of T. spiralis with ABZ, then metabolome of the parasites were extracted. Following liquid chromatography-tandem mass spectrometry analysis, an approximately of 11,187-11,191 features were identified from XCMS online platform. From the metabolome data, there were 122 and 133 metabolites those were significantly changed by ABZ treatment in adult and larval stages, respectively. The pathway analysis was performed with Metaboanalyst platform and fatty acid degradation pathway was highlighted in both stages of the parasites. This pathway is vital for lipid metabolism of the worms, hence, we screened for potential drug targets in this pathway. We found that Carnitine palmitoyl transferase (CPT) 1 and 2 are the enzymes responsible for transporting fatty acids into mitochondria. Inhibiting these enzymes would shut down the lipid metabolism machinery of the parasites. Hence, these enzymes were proposed as the potential drug targets for trichinellosis treatment in the future.
Institute	Chulabhorn Royal Academy
Department	Princess Srisavangavadhana Faculty of Medicine
Last Name	Chienwichai
First Name	Peerut
Address	906, Kamphaeng Phet 6 Rd., Lak Si, Bangkok, 10210, Thailand
Email	peerut.chi@cra.ac.th
Phone	+6681687460
Submit Date	2025-06-06
Raw Data Available	Yes
Raw Data File Type(s)	mzML, wiff
Analysis Type Detail	LC-MS
Release Date	2025-08-26
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR002490
Project DOI:	doi: 10.21228/M8SC2K
Project Title:	Metabolomic profiles of albendazole treated T. spiralis worms
Project Summary:	Trichinella spiralis is the parasitic nematodes that cause trichinellosis. Patients are infected with T. spiralis by consuming raw meat containing larval stage of the parasite. Patients may develop weakness, muscle pain, facial edema, or death in severe cases. Albendazole (ABZ) is the drug of choice for trichinellosis, however, the resistance to ABZ has been repeatedly reported. Hence, novel drugs against this parasite are essentially required. Developing new drugs is expensive and time-consuming. To overcome these limitations, the application of computational approaches and drug repurposing strategy would be a suitable solution. Here, we aimed to discover new anthelmintic drugs for T. spiralis using in silico-based techniques and in vitro validation. Firstly, we treated both adult and larval stages of T. spiralis with ABZ, then metabolome of the parasites were extracted. Following liquid chromatography-tandem mass spectrometry analysis, an approximately of 11,187-11,191 features were identified from XCMS online platform. From the metabolome data, there were 122 and 133 metabolites those were significantly changed by ABZ treatment in adult and larval stages, respectively. The pathway analysis was performed with Metaboanalyst platform and fatty acid degradation pathway was highlighted in both stages of the parasites. This pathway is vital for lipid metabolism of the worms, hence, we screened for potential drug targets in this pathway. We found that Carnitine palmitoyl transferase (CPT) 1 and 2 are the enzymes responsible for transporting fatty acids into mitochondria. Inhibiting these enzymes would shut down the lipid metabolism machinery of the parasites. Hence, these enzymes were proposed as the potential drug targets for trichinellosis treatment in the future.
Institute:	Chulabhorn Royal Academy
Department:	Princess Srisavangavadhana Faculty of Medicine
Last Name:	Chienwichai
First Name:	Peerut
Address:	906, Kamphaeng Phet 6 Rd., Lak Si, Bangkok, 10210, Thailand
Email:	peerut.chi@cra.ac.th
Phone:	+66816874608

Subject:

Subject ID:	SU004112
Subject Type:	Invertebrate
Subject Species:	Trichinella spiralis

Factors:

Subject type: Invertebrate; Subject species: Trichinella spiralis (Factor headings shown in green)

mb_sample_id	local_sample_id	Sample source	Stage	Treatment
SA454259	20220526_Trichinella larva 100ng AB2_2	T. spiralis	Larva	ABZ treatment
SA454260	20220526_Trichinella larva 100ng AB2_1	T. spiralis	Larva	ABZ treatment
SA454261	20220526_Trichinella larva 100ng AB2_3	T. spiralis	Larva	ABZ treatment
SA454262	20220526_Trichinella larva 100ng AB2_4	T. spiralis	Larva	ABZ treatment
SA454263	20220526_Trichinella larva 100ng AB2_5	T. spiralis	Larva	ABZ treatment
SA454264	20220526_Trichinella larva 0.1% DMSO_1	T. spiralis	Larva	Control
SA454265	20220526_Trichinella larva 0.1% DMSO_2	T. spiralis	Larva	Control
SA454266	20220526_Trichinella larva 0.1% DMSO_3	T. spiralis	Larva	Control
SA454267	20220526_Trichinella larva 0.1% DMSO_4	T. spiralis	Larva	Control
SA454268	20220526_Trichinella larva 0.1% DMSO_5	T. spiralis	Larva	Control

Showing results 1 to 10 of 10

Showing results 1 to 10 of 10

Collection:

Collection ID:	CO004105
Collection Summary:	Trichinella spiralis larval worms were treated with IC50 concentration of albendazole, then the worms were collected for metabolite extraction
Sample Type:	Worms

Treatment:

Treatment ID:	TR004121
Treatment Summary:	Worms were treated with IC50 concentration of albendazole

Sample Preparation:

Sampleprep ID:	SP004118
Sampleprep Summary:	All worms from each condition were transferred into 1.5-mL microcentrifuge tubes and homogenized in 500 μL methanol. At which point, the tubes were snap-frozen in liquid nitrogen and thawed prior to centrifuging at 800 × g for 1 min at 4°C. The supernatant was collected and placed in a new tube, and the pellet was extracted again with the same protocol. Following centrifugation, the supernatant from the second extraction was pooled into a tube containing the supernatant from the first extraction. The pellet was resuspended in 250 μL of deionized H2O before snap-freezing in liquid nitrogen and thawing. The supernatant was obtained by centrifugation at 15,000 × g for 1 min at 4°C and then pooled with the previous tube. The tubes containing the pooled supernatants were centrifuged at 15,000 × g for 1 min at 4°C to remove the remaining debris. The clear supernatant was transferred to a new tube and later dried in a speed vacuum.

Sampleprep ID:

SP004118

Sampleprep Summary:

All worms from each condition were transferred into 1.5-mL microcentrifuge tubes and homogenized in 500 μL methanol. At which point, the tubes were snap-frozen in liquid nitrogen and thawed prior to centrifuging at 800 × g for 1 min at 4°C. The supernatant was collected and placed in a new tube, and the pellet was extracted again with the same protocol. Following centrifugation, the supernatant from the second extraction was pooled into a tube containing the supernatant from the first extraction. The pellet was resuspended in 250 μL of deionized H2O before snap-freezing in liquid nitrogen and thawing. The supernatant was obtained by centrifugation at 15,000 × g for 1 min at 4°C and then pooled with the previous tube. The tubes containing the pooled supernatants were centrifuged at 15,000 × g for 1 min at 4°C to remove the remaining debris. The clear supernatant was transferred to a new tube and later dried in a speed vacuum.

Chromatography:

Chromatography ID:	CH004966
Instrument Name:	Agilent 1260
Column Name:	Waters Acquity BEH C8 (100 x 2.1 mm, 1.7 μm)
Column Temperature:	40°C
Flow Gradient:	5% mobile phase B for 2.0 min (0.0–2.0 min), 5%–60% B for 0.5 min (2.0–2.5 min), 60%–80% B for 1.5 min (2.5–4.0 min), 80%–100% B for 8.0 min (4.0–12.0 min), 100% B for 5 min (12.0–17.0 min), 100%–5% B for 0.1 min (17.0–17.1 min), and 5% B for 2.9 min (17.1–20.0 min).
Flow Rate:	0.3 mL/min
Solvent A:	100% Water; 0.1% Formic acid
Solvent B:	100% Acetonitrile; 0.1% Formic acid
Chromatography Type:	Reversed phase

Analysis:

Analysis ID:	AN006546
Analysis Type:	MS
Chromatography ID:	CH004966
Has Mz:	1
Has Rt:	1
Rt Units:	Minutes
Results File:	ST003975_AN006546_Results.txt
Units:	m/z

Analysis ID:	AN006547
Analysis Type:	MS
Chromatography ID:	CH004966
Has Mz:	1
Has Rt:	1
Rt Units:	Minutes
Results File:	ST003975_AN006547_Results.txt
Units:	m/z